LifeCycle Pharma Submits Phase III Protocol for LCP-Tacro to FDA

LifeCycle Pharma A/S announced that LCP has submitted the phase 3 protocol for LCP-Tacro in de novo kidney transplant recipients to the Food and Drug Administration in [the] United States.
StreetInsider